Cylene Pharmaceuticals Inc. is a private, Phase II clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Cylene was co-founded by Daniel Von Hoff, MD, one of the leading oncology clinical investigators in the world. Dr. Von Hoff serves Cylene as the Vice President of Medical Affairs, as the Chairman of the Clinical Advisory Board and as a member of the Board of Directors. His vision to take cancer drugs seamlessly from concept to clinical proof-of-concept has shaped Cylene’s strategic plan.
Cylene has created a diverse portfolio of product candidates (see Figure below) using two separate discovery platforms, both of which are internal and proprietary and have delivered multiple agents with substantial market potential. One discovery platform creates first-in-class inhibitors of Serine/Threonine protein kinases while the other creates novel RNA Polymerase I (Pol I) Targeting Agents. Moreover, Cylene has built a strong intellectual property estate around both platforms and owns full rights to all agents in the pipeline. Cylene’s record of creativity, execution, frugality and pipeline creation and advancement have enabled the company to attract top tier corporate (Novartis BioVenture Fund, Lilly Ventures and Celgene Corporation) and classic venture capital investors (Sanderling, HBM, Bioventure Investors and others).